Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6329041 | 0.99 | PPARG (0.45) | PPARGPPARAPPARDALDH1A1MAPK1 | |
| SCHEMBL6334752 | 0.93 | PPARG (0.53) | PPARGPPARAPPARDALDH1A1TRPV4 | |
| SCHEMBL6334908 | 0.93 | PPARG (0.43) | PPARGPPARAPPARDALDH1A1TRPV4 | |
| SCHEMBL6327220 | 0.91 | RORC (0.38) | PPARGPPARAPPARDALDH1A1TRPV4 | |
| SCHEMBL6328743 | 0.90 | PPARG (0.38) | PPARGPPARAPPARDTRPV4MAPT | |
| SCHEMBL6326601 | 0.90 | PPARG (0.38) | PPARGPPARAPPARDALDH1A1MAPK1 | |
| SCHEMBL6329990 | 0.90 | NPY1R (0.38) | PPARGPPARAPPARDALDH1A1TRPV4 | |
| SCHEMBL6330468 | 0.89 | PPARG (0.37) | PPARGPPARAPPARDTRPV4MAPT | |
| SCHEMBL6327387 | 0.89 | NPY1R (0.39) | PPARGPPARAPPARDALDH1A1TRPV4 | |
| SCHEMBL6328165 | 0.89 | PPARG (0.47) | PPARGPPARAPPARDTRPV4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014805-A1 | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014805-A1 | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity | GPR119, EGLN3, PC | PPARG 13/4885PPARA 49/4885PPARD 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.